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BACKGROUND AND PURPOSE
The clinical effects of anti-angiogenic agents remain controversial. Therefore, elucidating the pharmacological properties of
these compounds is a pivotal issue.
EXPERIMENTAL APPROACH
The effects of treatment with sunitinib on tumour and normal tissues of mice bearing C-26 adenocarcinoma cells were
analysed by matrix-assisted laser desorption ionization MS imaging (MALDI-MSI). Expression of the key targets of sunitinib –
angiogenic receptors – was studied by immunofluorescent labelling.
KEY RESULTS
MALDI-MS assays showed that sunitinib and its fragment ions were present throughout tumour and normal tissues. Major
metabolites were identified in blood and solid tissues, while minor drug metabolites were detectable only in blood. Tumour
growth and intratumour VEGF receptor-2 expressions were significantly reduced in sunitinib-treated mice, while the
expression of the other targeted receptors, PDGF receptor -α or -β and fibroblast growth factor receptor-1, remained
unaffected. Within tumour tissue, the close proximity of sunitinib metabolites to the precursor ion suggested in situ
metabolism of the administered drug. There were intratumour areas where the signal intensity of sunitinib correlated with
expression of VEGF receptor-2.
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CONCLUSIONS AND IMPLICATIONS
This is the first study that demonstrates MALDI-MSI is a versatile platform to study the intratumour localization of an
unlabelled anti-angiogenic drug. The combination of MALDI-MSI and immunofluorescence analysis can provide further
insights into the molecular interaction of drug compounds and their targets within tumour tissue.
Abbreviations
ACN, acetonitrile; ADME, adsorption, distribution, metabolism, elimination; AGC, automatic gain control; C-26,
colon-26 adenocarcinoma cell line; CYP3A4, cytochrome P450 3A4; FGFR, fibroblast growth factor receptor;
FT, Fourier transform; MALDI, matrix-assisted laser desorption ionization; MSI, MS imaging; m/z, mass-to-charge
ratio; PDGFR, PDGF receptor; RTK, receptor tyrosine kinase; RTKI, receptor tyrosine kinase inhibitor; VEGFR, VEGF
receptor
Introduction
The pharmacological properties of novel drug candidates are
routinely characterized during the preclinical phase of drug
development. However, despite the fact that the adsorption,
distribution, metabolism and elimination (ADME) of drug
compounds can critically influence their therapeutic benefit,
in-depth and routine determination of these parameters
became the focus of research only in the last decades. Until
recently, extensive ADME studies were conducted rather late
in the process of drug development, mainly in phase I clinical
studies. This may be one of the key factors behind the low,
11%, overall first-in-man to registration rate of novel drug
candidates in the 1990s. This proportion was especially poor
(5%) among drugs in the field of oncology (Kola and Landis,
2004).
The vasculature is essential for the maintenance of the
necessary oxygen and nutrient supply to malignant cells
during tumourigenesis (Dome et al., 2007). Accordingly, starv-
ing the tumour with the inhibition of endothelial growth by
anti-angiogenic agents became a widely investigated and
applied treatment strategy in the last decade (Waldner and
Neurath, 2012). However, both experimental and clinical
results with these drugs are controversial (Amir et al., 2009;
Loges et al., 2010; Jayson et al., 2012; Moreno Garcia et al.,
2012; Rapisarda and Melillo, 2012; Abe and Kamai, 2013).
Response to treatment often manifests itself as an increase in
progression-free survival, but it rarely results in an overall
survival benefit (Xiao et al., 2013). Thus, evaluating the ADME
of these agents is a crucial step in drug development. Besides
monoclonal antibodies, receptor tyrosine kinase inhibitors
(RTKIs) represent the main focus of anti-angiogenic research.
Among the RTKIs, sunitinib (SU11248, Sutent®, Pfizer, New
York, NY, USA) is the most widely used in clinical practice. It
is a multi-target RTKI, blocking the signalling of the key
angiogenic receptors, the VEGF receptors (VEGFRs), the PDGF
receptors (PDGFRs) and the FGF receptors (FGFRs) (Mendel
et al., 2003; Sun et al., 2003). Between 2006 and 2011, the
Food and Drug Administration approved sunitinib for the
treatment of advanced gastrointestinal stromal tumour after
disease progression or intolerance to imatinib mesylate
(Cananzi et al., 2013), of advanced renal cell carcinoma
(Choueiri, 2013) and also of progressive, undifferentiated,
unresectable, locally advanced or metastatic pancreatic neu-
roendocrine tumour (Peng and Schwarz, 2013).
The use of MALDI-MS spectroscopic techniques in phar-
macological studies dates back to the mid 1990s when in vitro
metabolites were characterized by this technique (Chung
et al., 1995; Ding et al., 1995; Hooker et al., 1995; Gusev et al.,
1996). The development of matrix-assisted laser desorption
ionization MS imaging (MALDI-MSI), as a method to deter-
mine the spatial distribution of drugs and their metabolites at
histologically relevant resolution, was an important advance
in studying drug action (Khatib-Shahidi et al., 2006). Com-
pared with other methods, which localize drugs in situ, such
as autoradiography or PET, MALDI-MSI is label-free and can
be applied to native drug structures and their metabolites
within any tissue environment. Using this technology, we
have recently provided evidence showing the exact tissue
compartment localization of low MW drugs administered to
patients (Fehniger et al., 2011; Marko-Varga et al., 2012). To
date no imaging data on the distribution of an anti-
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angiogenic agent has been reported. Taking into considera-
tion that the anti-angiogenic effect on the tumour vessel
network may influence the distribution of the anti-
angiogenic drug itself, such spatial distribution data could
greatly help researchers to better understand the mode of
action of these agents.
In the current study, we present data on the detection and
distribution of sunitinib, its metabolites and its target recep-
tors in normal and tumour tissues of mice bearing C-26
adenocarcinoma, by MALDI-MSI and immunofluorescent
imaging respectively. Our results provide the first evidence
that MALDI-MSI can be used to conduct ADME studies on
low MW anti-angiogenic drugs.
Materials and methods
In vivo tumour model and treatments
All animal care and experimental procedures complied with
the animal welfare regulations of the Department of Experi-
mental Pharmacology, National Institute of Oncology,
Budapest, Hungary and were approved by the Institute (per-
mission number: 22.1/722/3/2010). Experiments involving
animals are reported in accordance with the ARRIVE guide-
lines (Kilkenny et al., 2010; McGrath et al., 2010). A total of
52 animals were used in the experiments described here.
Female Balb/C mice (10 weeks old) from our colony
(National Institute of Oncology, Budapest) were maintained
on a daily 12-h light/12-h dark cycle and were housed under
pathogen-free conditions in microisolator cages with labora-
tory chow and water ad libitum. The mouse colon-26 adeno-
carcinoma cell line [C-26, CLS (Cell Line Service), Mason
Research Institute, Eppelheim, Germany] was cultured in
RPMI 1640 with 10% FBS and 1% penicillin/streptomycin (all
from Sigma-Aldrich, Steinheim, Germany) at 37°C, 5% CO2
in a humidified atmosphere. Groups of five mice were inocu-
lated s.c. with 2 × 106 C-26 cells, as described recently (Manea
et al., 2011).
Sunitinib (LC Laboratories, Woburn, MA, USA; CAS. No.
557795-19-4) treatment began 2 weeks after tumour cell
injection and was performed once daily at a dose of
100 mg·kg−1 per os with a feeding tube five times a week
for 2 weeks. Sunitinib at >99% purity was suspended
in 2% carboxymethylcellulose with 2 mg·mL−1 methyl-4-
hydroxibenzoate (both from Sigma-Aldrich), while control
mice received only the suspending medium. Three hours
after the last treatment, peripheral blood was drawn from the
canthus and the animals were killed. Tumours, livers and
kidneys were removed and snap frozen by submerging the
tissues into liquid nitrogen-cooled isopentane, as described
previously (Dome et al., 2002).
Detection of the compound and analysis of
drug distribution
A MALDI LTQ Orbitrap XL mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) was used both for compound
characterization, drug detection in blood on MALDI target
plate and tissue imaging. For compound characterization,
drug was dissolved in 50% methanol (MeOH, Sigma-Aldrich)
at HPLC grade (>99.8%) at 1 mg·mL−1 stock concentration
and stored at 4°C. As matrix 7.5 mg·mL−1 α-cyano-4-
hydroxycinnamic acid (Sigma-Aldrich) was dissolved in 50%
acetonitrile (ACN; hypergrade for LC-MS; Merck, Darmstadt,
Germany) and 50% water, containing 0.1% trifluoroacetic
acid (Sigma-Aldrich). One microlitre of the compound solu-
tion was applied on the MALDI plate with 1 μL matrix solu-
tion. Full mass spectra were obtained using the Fourier
transform (FT) analyser (Orbitrap), sampling the spots in a
survey mode with positive polarity, collecting 20 experiments
in a single run with 60 000 resolution. The nitrogen laser was
set to 10 μJ and activated automatic gain control (AGC) was
used. For MS/MS experiments the detected precursor ion was
fragmentized at normal scan rate, isolating the ions with
mass-to-charge ratio (m/z) 1.0 width. The normalized colli-
sion energy (NCE) was 40% during an activation time of 30
ms and activation Q of 0.250 was applied in centroid mode.
For detection of the compound in blood, 20 μL of the
plasma sample was removed and ACN precipitation was per-
formed. Concentration and elution of the RTKI was imple-
mented with Pierce C18 Tips (Thermo Fisher Scientific,
Rockford, IL, USA) following the manufacturer’s instructions.
One microlitre of the sample was applied on the MALDI plate
with 1 μL matrix solution using the same instrument settings
as used for the compound characterization.
For tissue drug imaging, 10 μm frozen sections were cut
using a cryotome and placed on glass slides. After drying of
the tissue, 0.5 mL of the matrix solution was deposited step-
wise by an airbrush to avoid wetting. In order to control the
spraying conditions, the position of the airbrush was kept
constant. Full mass spectra were obtained using the Orbitrap
mass analyser at 60 000 resolution (at m/z 400). Tissue sec-
tions were sampled in the 150−800 Da mass range in positive
mode with 100 μm raster size. The nitrogen laser was oper-
ated at 10.0 μJ with AGC on. For MS/MS data collection, the
observed sunitinib peak at m/z 399.218 was fragmentized at
normal scan rate, with m/z 1.0 width isolation window, using
40% NCE, 30 ms activation time and 0.250 activation Q. The
minimal signal required for MS/MS spectra generation by
the linear ion trap analyser was 500 counts. Analysis of the
spectra was implemented with Xcalibur v 2.0.7. software,
while visualization of the drug and fragment ions was per-
formed with the ImageQuest™ software (both from Thermo
Fisher Scientific, San José, CA, USA).
Quantification of the precursor compound
For in tissue quantification, calibration curves of the drug
compound were established on control tissue sections of
tumour, liver and kidney from mice. Sunitinib was dissolved
and diluted stepwise in 50% methanol. From each concen-
tration, 0.5 μL was applied onto the tissue surface within the
concentration range of 0.00016–2.5 μmol·mL−1. Spraying and
detection conditions were the same as those used for the
tissue sample analysis. Calibration curves were created by
Quantinetix software (ImaBiotech, Loos, France).
Analysis of target receptor and drug
co-localization
For the analysis of target receptor and drug co-localization,
five serial frozen sections were cut from each tumour. Section
#3 was used to analyse the distribution of the RTKI by
BJP S Torok et al.
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MALDI-MSI and for haematoxylin and eosin (HE) staining
(Supporting information, Figures S1 and S2). Sections #1–2
and #4–5 were labelled sequentially with either of the follow-
ing primary antibodies: anti-VEGFR-2 (1:50, Cell Signaling
Technology, Danvers, MA, USA; Catalogue number: 55B11),
anti-PDGFR-α (1:50, Cell Signaling Technology; Catalogue
number: D1E1E), anti-PDGFR-β (1:50, Cell Signaling Technol-
ogy; Catalogue number: C82A3) or anti-FGFR-1 (1:50, Cell
Signaling Technology; Catalogue number: D8E4). All the
primary antibodies were labelled with a fluorescent secondary
antibody (anti-rabbit Alexa-488, 1:1000, Cell Signaling Tech-
nology; Catalogue number: 4412). Nuclei were stained with
Hoechst 33342 (Molecular Probes, Eugene, OR, USA) and
tumour sections were covered with ProlongGold Antifade
Reagent (20 μL, Invitrogen, Carlsbad, CA, USA; Catalogue
number: P36930). Slides were scanned by TissueFAXS (Tissue-
Gnostics GmbH, Vienna, Austria) and VEGFR-2, PDGFR-α, -β
and FGFR-1 expression patterns were analysed by two
pathologists (BD and TF).
Data analysis
Statistical analysis was performed to evaluate the in vivo
effects of sunitinib. Two diameters of the tumours were meas-
ured three times a week and tumour volume was calculated
with the formula: width2 × length × π / 6. Difference between
the treated and the control groups in tumour volume and
weight was analysed by the Mann–Whitney U-test. Data were
considered significant when P ≤ 0.05. Data are based on five
independent experiments.
Results
Sunitinib treatment inhibits tumour growth
Syngeneic subcutaneous mouse tumour models are ideal and
widely used in translational medicine studies allowing us to
evaluate the efficacy of various anticancer agents including
anti-angiogenic drugs (Paku et al., 2011; Wong et al., 2012).
Therefore, we decided to compare the effect of sunitinib treat-
ment on tumour development with measures of drug distri-
butions within the tumours. Balb/C mice were injected s.c.
with C-26 mouse colon adenocarcinoma cells and 2 weeks
later were dosed daily with sunitinib over a 2 week period.
Tumours and other tissues were then obtained and analysed.
The mean tumour weights in the control and sunitinib-
treated groups were 0.274 and 0.090 g respectively
(Figure 1A; P = 0.0635). More importantly, a 2 week sunitinib
treatment resulted in a significant (P = 0.0159) relative
tumour growth inhibition as well (Figure 1B).
MALDI-MSI identification of sunitinib and its
fragment ions
We started our MALD-MSI studies by identifying the monoi-
sotopic mass of pure stock sunitinib compound dried as a
droplet at m/z 399.218 (Figure 2A). Subsequent MS/MS frag-
mentation of the precursor ions led to the loss of the terminal
diethylamino group, generating a fragment ion at m/z 326.1,
while the presence of fragment ion at m/z 283.1 indicated a
cleavage at the amide group (Figure 2B).
Identification of sunitinib and its metabolites
in blood
Adsorption of the drug was examined in peripheral blood.
Sunitinib was measured in all plasma samples taken just
before killing the animals. Moreover, metabolites of the pre-
cursor compound were also traceable and could be character-
ized. Presumed structures and MS/MS spectra of the precursor
compound and its metabolites in blood plasma are presented
in Figure 3.
The previously described bis-desethylated metabolite
(M1) of sunitinib (Speed et al., 2012), with a monoisotopic
mass at m/z 343.000 could be detected only in a few blood
samples performing full mass scans. However, isolating and
fragmenting the proposed monoisotopic peak of that
metabolite resulted in fragment ions at m/z 326.2 and 283.1
in all samples. Stepwise elevation of the collision energy
proved that the detected fragment ions are formed by the
fragmentation of M1. The missing precursor ion in full mass
spectra may be explained by the low concentration of M1
Figure 1
Sunitinib reduces the in vivo growth of C-26 mouse colon adenocar-
cinoma cells in Balb/C mice. (A) Tumour weights and (B) percentage
of change of tumour volumes of control and sunitinib-treated groups
(100% refers to day #1 of the treatments). Data are shown as box
(first and third quartiles) and whisker (maximum to minimum) plots
with the median (horizontal bar) from 5 animals per group. *P =
0.0635, **P = 0.0159, versus control.
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that appeared to be below the detection limit of the FT
analyser compared with the linear ion trap.
The signal generated at m/z 358.120 of M2 indicates the
loss of the terminal diethylamine group, with the oxidation
of the molecule. This resulted in a fragment ion at m/z
283.1, but not at m/z 326.1. The presence of fragment ion
at m/z 340.2 refers to the terminal dehydroxilation of the
molecule.
M3, an active metabolite of sunitinib (SU012662) (Rais
et al., 2012) was formed by the mono-desethylation of the
molecule, resulting a monoisotopic mass of m/z 371.188 and
the same fragment ions as sunitinib.
Two mono-hydroxylated variations of the active metabo-
lite were detected at m/z 387.182. M4 was modified at the
indolylidene-dimethylpyrrole moiety, resulting a fragment
ion at m/z 299.1. M5 was hydroxylated at the carbon next to
Figure 2
(A) Full mass spectrum of sunitinib and images of the distribution of the precursor molecule in tumour, liver and kidney tissues after 2 weeks of
treatment. Signal of sunitinib is normalized to total ion current (TIC). (B) MS/MS spectrum of sunitinib and images of the distribution of the
fragment ions (m/z 326.1 and 283.1) in tumour, liver and kidney tissues.
BJP S Torok et al.
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the amide nitrogen, which generated a fragment ion at m/z
283.1. The detected fragment ion peak at m/z 369.1 could be
derived from both molecules by dehydroxylation, such as m/z
342.2 by the loss of the etylamino group.
Loss of two hydrogen atoms of the terminal ethyl groups
of sunitinib generated a metabolite (M6) at m/z 397.202.
Fragmentation of the molecule generated ions at m/z 326.1
and 283.1.
Fragment ions of a previously described metabolite with
the monoisotopic mass of m/z 397.224 (M7) could also be
detected by MS/MS (Speed et al., 2012). Signals of fragments
were generated at m/z 324.2 and 281.2, suggesting defluori-
nation and subsequent dehydroxylation of the molecule. M7
was not traceable by full MS, probably because of the signal
suppression of M6 at m/z 397.202.
As with M1, the saturated metabolite of sunitinib, M8,
was detected by Speed et al. at m/z 401.00 in rat and monkey
faeces (Speed et al., 2012). This could only be rarely measured
in our mouse model by full MS. However, when isolating
the presumed metabolite peak, the detected fragment ions
at m/z 285.1 and 328.2 indicated the presence of the mol-
ecule, and that the saturation occurred at the indolylidene-
dimethylpyrrole moiety.
Mono-hydroxylated metabolites of sunitinib were also
measured at m/z 415.214. Fragmentation of the molecule
indicated the oxidation on the indolylidene-dimethylpyrrole
group (M9) with 16 Da higher fragments than the corre-
sponding ions of sunitinib at m/z 342.2 and 299.2. Moreover,
upon fragmentation of the detected metabolite peak, ions at
m/z 326.1 and 283.1 were also formed, indicating that the
oxidation occurred either at one of the terminal carbons of
the diethylamine group (M10) or at the amine moiety (M11).
M11 was previously synthesized as SU012487 (Speed et al.,
2012). Dehydroxylation of any of the mono- hydroxylated
metabolites could result in a fragment ion at m/z 397.1.
M12 at m/z 495.283 was identified as a sulphate conjugate
of M9. Desulphuration of the molecule gave rise to the frag-
ment ion at m/z 415.2, while dehydroxylation resulted in a
fragment ion at m/z 477.3.
The glucuronide metabolite, M13, was detected at m/z
575.252. The cleavage at the amide group and the loss of the
terminal diethylamino moiety resulted in fragment ions at
459.2 and 502.2 respectively.
The metabolite at m/z 591.243 (M14) was generated by
both the oxidation and the glucuronidation of sunitinib.
When the molecule fragmentized as the unmodified com-
pound, ions at m/z 518.2 and 475.1 were generated. Dehy-
droxylation eventuated in a signal at m/z 573.2, while the
fragment ion at m/z 415.2 was formed by the loss of the
dehydrated glucuronic acid. Deglucuronidation and dehy-
droxylation of the molecule resulted in an ion at m/z 342.2.
M3, the active metabolite generated a two- to threefold
less-intensive signal than the precursor molecule in blood
samples. All the other metabolites were only traceable, with
less than 5% of the signal intensity of the unmodified com-
pound (data not shown).
Distribution of administered sunitinib in
tumour, liver and kidney tissue sections
The distribution of sunitinib in tumour, liver and kidney
tissue samples was examined by MALDI-MSI. The precursor
compound with its fragment ions could be detected in all
of the tissues mentioned earlier. Representative examples
showing the distribution of sunitinib and its fragment ions
are shown in Figure 2. The intratumour localization of the
compound was predominantly peripheral, which can either
be related to the histological or to the capillary network
structures of the tissues. No major intertumour heterogeneity
was seen among the sunitinib-treated replicates. Sunitinib
and its fragment ions showed co-localization within the
tissues. This co-localization can be interpreted as a molecular
fingerprint that confirms the identity of sunitinib in these
measurements.
We also identified several sunitinib metabolites within
the tumour tissue. In particular, the mono-desethylated (m/z
371.188), the desaturated (m/z 397.203), and the mono-
hydroxylated (m/z 415.215) metabolites were observable by
imaging (Figure 4). The precursor compound, its fragment
ions and all the measured metabolites showed an overlapping
tissue pattern.
Quantification of sunitinib in tumour, liver
and kidney tissue samples
Quantification of the drug compound on tissue sections
displayed a linear correlation between concentration and
signal intensity when normalized to the matrix signal (m/z
379.093). This linearity was found to be between the concen-
tration range of 0.16 nmol·mL−1 and 0.5 μmol·mL−1 in the
case of liver and tumour tissues, while it was in the range of
0.16 nmol·mL−1 and 0.1 μmol·mL−1 in the case of kidney sec-
tions. The signal intensity of the manually deposited drug
solution was the highest from kidney tissue and the lowest
from the tumour section. Possible explanations of this phe-
nomenon could be variations in cell density and/or in the
physicochemical properties of these tissue types. Calibration
curves of sunitinib obtained on tumour, liver and kidney
tissue sections are shown in Figure 5.
Co-localization of drug compound and its
target receptors in tumour tissue
The receptor proteins targeted by sunitininb were expressed
by C-26 adenocarcinoma cells grown s.c. In these tumour
cells, the patterns of expression of these targets was focal for
VEGFR-2 or diffuse, for PDGFR-α, PDGFR-β and FGFR-1.
Typical patterns of immunofluorescent stainings in frozen
tumour tissue samples are shown in Figure 6. In line with the
finding mentioned earlier that drug treatments resulted in
significantly slower tumour growth in vivo, we also found
reduced intratumour expressions of the key angiogenic recep-
tor VEGFR-2 in sunitinib-treated animals (Figure 6A), com-
pared with controls (Figure 6C). However, this phenomenon
was not accompanied by alterations in the VEGFR-2 staining
pattern, which remained focal (Figure 6A). It is also impor-
tant to mention that sunitinib treatments did not affect the
expression of PDGF or FGF receptors (Figure 6A).
Sunitinib was measured by MALDI-MSI by monitoring
the m/z 399.218 ion mass, using 100 μm rastering over the
entire tumour cryosection. In Figure 6B, an intensity map is
shown, generated by point-by-point sampling, locating the
major depots of the drug. In serial sections of sunitinib-
treated tumours, the drug distribution as visualized by
MALDI-MSI did not show an obvious overlap with the tissue
BJPSunitinib and its target receptors in mice
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labelling patterns of any of its target receptors. However,
composite pictures made from the combination of
MALDI-MS and immunofluorescent images identified areas
where the highest concentrations of sunitinib were found in
the same locations that expressed the highest concentrations
of VEGFR-2 (Figure 6B). Nevertheless, this latter preliminary
observation has to be confirmed by further in-depth studies.
Discussion
Sunitinib is metabolically transformed by cytochrome
P450 3A4 (CYP3A4) to its active, desethylated metabolite,
SU012662 (M3), which is then further modified by CYP3A4
to inactive forms (Rock et al., 2007). After administration
of a single oral dose, 23–37% of sunitinib is converted to
SU012662 in humans (Houk et al., 2010), underlining the
importance of studies evaluating the metabolism of such
antitumour drugs in appropriate preclinical settings. Our
study confirmed that M3 is the major plasma metabolite
present, not only in rats, monkeys and humans, as found by
Speed et al. (Speed et al., 2012), but also in mice. In plasma
samples, the signal of this desethylated metabolite was an
order of magnitude higher than that of other modified com-
pounds. Although SU012662 generated an order of magni-
tude lower signal intensity in tissue than sunitinib, this was
not necessarily higher than that generated by the other
detectable metabolites. This observation can be explained not
only by the potential difference in concentration, but also by
the different ionizing properties of sunitinib and its deriva-
tives in different tissues.
In the present study, the drug compound and its metabo-
lites were not directly quantified. As the calibration curves we
developed for this study showed linear correlation between
concentration and signal intensity, such analysis could also be
performed by MALDI-MSI by carefully considering the differ-
ences of signal intensities originating from different tissues.
By preparing calibration curves of syntheticmetabolites, accu-
rate studies can be implemented to follow the fate of the
original molecule and each of its derivatives in the body.
The observed overlap in the distribution pattern of suni-
tinib and its metabolites, as detected in the tissue, suggests
Figure 4
Distribution properties of sunitinib and its metabolites. Precursor molecule, desethylated metabolite (SU012662, M3), desaturated metabolite
(M6) and mono-hydroxylated metabolites (M9, M10 and/or M11) in tumour, liver and kidney tissue sections.
BJP S Torok et al.
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Figure 5
Quantification of sunitinib. Diagrams of MS signal intensities of sunitinib (normalized to matrix) in a concentration range of 0.064–1000 μg·mL−1
obtained from (A) tumour, (B) liver and (C) kidney tissue sections.
BJPSunitinib and its target receptors in mice
British Journal of Pharmacology (2015) 172 1148–1163 1157
that the chemical properties responsible for drug dispersion
remain similar in the case of the metabolites, and accord-
ingly, that they may contribute to the tumour growth
inhibitory activity of the precursor compound as well. Alter-
natively, the co-localization of sunitinib and its metabolites
may indicate that the drug is being taken up and metabolized
locally rather than being transported from other sites of
metabolism, such as the liver, back to the same location as the
precursor drug. Further studies in tissue are warranted to
confirm or rule out these assumptions.
Most of the techniques that have analysed sunitinib and
its derivatives are based on liquid chromatography coupled
with mass spectrometric detection (Baratte et al., 2004; de
Bruijn et al., 2010; Zhou and Gallo, 2010; Lankheet et al.,
2011; Rodamer et al., 2011; Rais et al., 2012; Speed
et al., 2012; Qiu et al., 2013). However, Etienne-Grimaldi et al.
described an HPLC method linked to UV detection of suni-
tinib and SU12662 in human plasma (Etienne-Grimaldi et al.,
2009). The m/z values of the precursor drug and its derivatives
in our study are consistent with these earlier results. The
Figure 6
Intratumour distribution patterns of sunitinib and its target RTKs in sunitinib-treated (A, B) and control (C) mice as visualized by MALDI-MSI and
immunofluorescent labelling respectively. In both (A) and (C), the tumours are immunolabelled for VEGFR-2, PDGFR-α, PDGFR-β and FGFR-1
(green). Nuclei are counterstained with Hoechst 33342 (blue). Note the focal (VEGFR-2) and diffuse (PDGFR-α, PDGFR-β, FGFR-1) expression
patterns of the tumour cells in both animal groups. Panel B shows an example for coincidence of drug location and targeted receptor in tumour.
MALDI-MSI detected sunitinib (m/z 399.218) at high signal intensities in the mantle and in this case in a central area as well. Signal intensity
gradients of the drug were seen in discrete compartments throughout the tissue (left picture). In order to investigate the occurrence of cells bearing
VEGFR-2 and the distribution of the drug, we first imaged the isolated VEGFR-2 signal from the RGB signal and then overlaid this image with the
drug contour map. The highest density of VEGFR-2 bearing cells (red dots) was congruent with the highest concentrations of the drug (right
picture). In (A) and (C), the three columns of immunofluorescent pictures (captured by a 20× objective) represent different magnifications of the
same image (100, 2000 and 8000%). White rectangles in the lower-power micrographs show the corresponding areas of the higher magnification
images.
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present study showed that MALDI-MS is also a powerful tool
to detect the drug compound ions and its metabolites. The
MALDI-MS experimental parts showed a slightly different
fragmentation pattern from electrospray ionization-MS
(Speed et al., 2012). Moreover, an advantage of MALDI-MSI
compared with other previously used methods is that the
earlier techniques require either fluid samples (such as blood
or sweat) or the homogenization of the tissue. Therefore, they
are not capable of analysing the spatial tissue distribution of
a compound in an organ or in a solid tumour.
Although the last half century has witnessed dramatic
advances in the field of medical imaging, there is still an
urgent need for the development of more advanced tech-
niques for imaging compounds in the drug discovery process.
This is particularly important in the narrowing of the selec-
tion of potential hits and leads as candidates for further
development. One of the reasons this has been difficult to
accomplish in the past is that until recently, the only avenue
for visualizing the in vivo distribution of drugs in targeted
tissues was to use labels, which are commonly radioactive,
Figure 6
Continued.
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and as such a safety risk. Methods such as PET and autoradi-
ography can provide information on the distribution of a
radiolabelled compound, even at the cellular level (Solon
et al., 2010; Solon, 2012). However, both of these methods
rely on quantitative data based upon the relative strength of
the label rather than the relative concentration of the drug.
For these reasons, unlabelled, that is ‘cold’ compounds will
provide evidence that relate to the drug structure only and
not to the labelling chemistry in a modified drug molecule. If
a drug is metabolized such that the label follows on the
fragment that is neither active, nor the precursor of an active
form, then the readout of distribution may have little to do
with the mode of action or the actual efficacy of the drug
(Solon, 2012). Other methods rely on the use of isotopes with
relatively short half-lives or fluorescent tags, which makes
long-term pharmacological analysis impossible or alters the
chemical structure and thus the binding affinity and/or
avidity to its target molecule (Solon et al., 2010).
From this point of view, it is particularly important that
methods be used that investigate the characteristics of the
unaltered native compound (i.e. the same agent as that being
administered to patients). MS is one such powerful tech-
nique, enabling the parallel determination of label-free drugs
and their metabolites. The Orbitrap mass analyser in the
hybrid instrument used in our study provides very high levels
of mass accuracy, to the tens of thousands fraction on a single
atomic mass unit (Strupat et al., 2009). This high accuracy in
identification allows strong statistical support for the mass
values that we have reported here for sunitinib as either
precursor ions, fragment ions, or metabolites formed in situ.
The MALDI-MSI technology also allowed label-free identifi-
cation of this small molecule compound, negating the
concern that drug properties could have been altered by the
labelling procedure. In principle, MALDI-MSI is not limited to
the analysis of low MW compounds, but it might also be
suitable for the localization of therapeutic macromolecules,
such as peptides (Craik et al., 2013) and antibodies (Glassman
and Balthasar, 2014). In practice, however, the identification
of specific antibodies by MALDI-MSI is a challenge as time-
of-flight instruments with broad mass range (over m/z 1
million) do not have sufficient resolution at high mass range,
while Orbitraps operate up to m/z 4000 (and thus unable to
detect singly charged peptides over 4 kDa). Enzymic in situ
digestion (Groseclose et al., 2007; Casadonte and Caprioli,
2011; Gustafsson et al., 2013) may provide unique peptides
that can help in their precise localization within tissue sec-
tions. However, the identification of these peptides is still
restricted to matching the accurate precursor masses in
MALDI-MS analysis with those observed in an LC-MS/MS
experiment used for peptide sequencing.
The current study is the first describing the tissue distri-
bution of an unlabelled anti-angiogenic RTKI and its metabo-
lites by MSI. In our study, the combination of the resolving
power of the Orbitrap with the sensitivity of the linear ion
trap made it an ideal technique for drug and metabolite
detection. We observed that oral administration of sunitinib
resulted in a systemic distribution of the drug throughout the
body with significant levels being observed in the blood,
liver, kidneys and tumour tissue. In this study, we have inves-
tigated the patterns of drug distribution in the animals fol-
lowing 2 weeks of daily sunitinib dosing. As such, we have
not studied the kinetics of drug accumulation in specific
tissue sites, or the kinetics of changes in the biological/
histological makeup of the tumours throughout the course of
treatment. We have clearly shown that sunitinib-treated
tumours showed areas of higher (typically peripheral) and
lower (tumour centre) drug signal intensities rather than a
homogeneous dispersal across the entire tumour. Of note,
this distribution pattern (i.e. higher signal intensity at the
tumour periphery vs. relatively lower levels in the central
tumour regions) proved to be reproducible throughout the
drug-treated tumour sample replicates. In accordance with
the findings of Domingues et al., we observed that VEGFR-2
expression was significantly reduced in treated tumours,
compared with untreated ones (Domingues et al., 2011). The
relationship between this reduction and the exposure to the
drug cannot be investigated in this study because of a single
time point of analysis. However, we can say that the time
point represented a window showing a clear biological effect
of the drug treatment, as seen by both a reduction in tumour
weight and volume.
Today, our understanding of the mode of action and the
efficacy of antivascular agents in oncology is especially
complex and peculiar. Accordingly, when interpreting our
findings, we need to take into consideration that both the
tumour tissue levels of sunitininb and the expression pattern
of its target receptors vary both spatially and temporally. The
actual tumour tissue level of an anticancer drug is always
influenced by the global blood supply of the tumour mass
and also by local intratumour blood flow changes (i.e. by the
distinct vascularization patterns of different intratumour
areas as well). Although they also have direct effect against
autocrine tumour cell signalling, the main effect of anti-
vascular agents (such as sunitinib) is exerted on the tumour
vasculature itself and, consequently, sunitinib influences the
efficacy of its own delivery. Additional key background infor-
mation is that sunitinib binds to its target receptors reversibly
and, moreover, that it may also result in significant changes
in the expression levels and patterns of its target receptors
(Roskoski, 2007). Our approach can contribute to the eluci-
dation of this complex biology in order to further develop
anti-angiogenic treatment strategies.
To the best of our knowledge, the current study provides
the first direct evidence that an anti-angiogenic drug given
orally is transported to, taken up and metabolized within the
targeted compartment, the adenocarcinoma tumour. Moreo-
ver, the presented results are the first demonstrating that
MALDI-MSI is a versatile and simple method of conducting
ADME studies on an anti-angiogenic RTKI. Hence, the current
study warrants further investigations to define the precise
and optimal role of MALDI-MSI in elucidating the mecha-
nisms of drug action and for validating transport to sites of
intended effect.
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Figure S1 After the MALDI-MSI analysis of tumour tissue
sections, the matrix was washed off the slides with 70%
ethanol and conventional haematoxylin and eosin (HE)
staining was performed. Figure S1 shows the HE-stained
section of the sunitinib-treated tumour shown in Figures 6B
and C respectively.
Figure S2 HE-stained section of the control tumour shown
in Figure 6C.
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